Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions

Bone Marrow Transplantation
K CwynarskiJ M Goldman

Abstract

Immune haemolytic anaemia (IHA) is a recognised complication after allogeneic stem cell transplantation (SCT) and occurs more frequently if marrow cells have been subjected to T cell depletion (TCD). Among 58 consecutive patients who underwent TCD-allogeneic SCT from volunteer unrelated donors for the treatment of CML at the Hammersmith Hospital during a 3-year period (1 March 1996 to 28 February 1999) we identified nine cases of IHA. All patients had a strongly positive direct and indirect antiglobulin test and in eight patients the serological findings were typical of warm-type haemolysis often with antibody specificities within the Rh system. All nine cases had clinically significant haemolysis and were treated initially with prednisolone and immunoglobulin. The onset of IHA coincided with the occurrence of leukaemic relapse in six cases, and the presence of host haemopoiesis confirmed by lineage-specific chimerism in all four cases studied. Five patients received donor lymphocyte infusions (DLI); in three molecular remission and the restoration of full donor chimerism coincided with resolution of haemolysis. We conclude that in the context of leukaemic relapse, DLI is an effective therapy for IHA following allografts involv...Continue Reading

References

Jun 1, 1991·British Journal of Haematology·A BasheyJ M Hows
Aug 1, 1980·The American Journal of Medicine·H M ShulmanE D Thomas
Jan 19, 1995·The New England Journal of Medicine·C L MackallS M Steinberg
Jan 23, 1999·Current Opinion in Immunology·D Mason, F Powrie
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L H SehnR J Soiffer

❮ Previous
Next ❯

Citations

Dec 6, 2006·The Tohoku Journal of Experimental Medicine·Izumi IshikawaTakeshi Sasaki
Mar 28, 2008·Wiener klinische Wochenschrift·Peter Valent, Klaus Lechner
Sep 30, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Meng WangAleksandar Mijovic
Sep 3, 2005·American Journal of Hematology·Muzaffar H QazilbashRichard Champlin
May 28, 2008·British Journal of Haematology·Aleksandar MijovicGhulam J Mufti
Apr 21, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Zhuoyan LiBipin N Savani
Apr 11, 2007·Advances in Cancer Research·Olle Ringdén
Mar 27, 2007·The Journal of Molecular Diagnostics : JMD·Zsolt JobbagyChristopher D Gocke
Oct 9, 2009·Leukemia Research·Anish ThomasChirag M Shah
May 29, 2002·Oncogene·Blanca Scheijen, James D Griffin
Apr 4, 2017·British Journal of Haematology·Quentin A HillUNKNOWN British Society for Haematology Guidelines
Jan 7, 2020·Clinical Medicine Insights. Blood Disorders·Tahseen Hamamyh, Mohamed A Yassin
Sep 4, 2020·Hematology/oncology and Stem Cell Therapy·Uroosa Ibrahim, Alla Keyzner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.